SCHEMBL14712957

SCHEMBL14712957

CCN1C(=O)C(=C/C=C/c2ccc(F)cc2)C(=O)N(CC)C1=S

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.57
MEN1 O00255 9/20 0.57
KMT2A Q03164 9/20 0.57
ALDH1A1 P00352 6/20 0.57
MDM2 Q00987 2/20 0.57
POLB P06746 2/20 0.57
HPGD P15428 2/20 0.57
KDM4C Q9H3R0 2/20 0.57
HTT P42858 2/20 0.57
KDM4E B2RXH2 1/20 0.57
THRB P10828 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
SMN1; SMN2 Q16637 4/20 0.46
NPSR1 Q6W5P4 3/20 0.46
MITF O75030 3/20 0.46
NTSR1 P30989 1/20 0.46
TNFRSF1A P19438 5/20 0.45
MAPK1 P28482 4/20 0.45
NPC1 O15118 1/20 0.45
LMNA P02545 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14712876 0.87 MAPT (0.59) MAPTMEN1KMT2AALDH1A1MDM2
SCHEMBL14712905 0.86 MAPT (0.57) MAPTMEN1KMT2AALDH1A1MDM2
SCHEMBL14712965 0.86 MAPT (0.64) MAPTMEN1KMT2AALDH1A1MDM2
SCHEMBL14712976 0.84 MAPT (0.56) MAPTMEN1KMT2AALDH1A1MDM2
SCHEMBL16543009 0.84 MAPT (0.55) MAPTMEN1KMT2AALDH1A1MDM2
SCHEMBL14712975 0.84 METAP1 (0.56) MAPTMEN1KMT2AALDH1A1MDM2
SCHEMBL14712973 0.83 MEN1 (0.55) MAPTMEN1KMT2AALDH1A1MDM2
SCHEMBL14713066 0.81 MEN1 (0.64) MAPTMEN1KMT2AALDH1A1MDM2
SCHEMBL14713000 0.80 MEN1 (0.60) MAPTMEN1KMT2AALDH1A1MDM2
SCHEMBL14305633 0.79 APP (0.63) MAPTMEN1KMT2AALDH1A1MDM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9994554-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-06-12 US disclosed
US-9994554-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-06-12 US disclosed
US-20180134691-A1 BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY NUHOPE, LLC (US) 2018-05-17 US disclosed
US-20180134691-A1 BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY NUHOPE, LLC (US) 2018-05-17 US disclosed
US-9878998-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-01-30 US disclosed
US-9878998-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-01-30 US disclosed
US-20150065531-A1 COMPOUNDS FOR USE IN CANCER THERAPY CONNOR, JAMES R. 2015-03-05 US disclosed
US-20150065531-A1 COMPOUNDS FOR USE IN CANCER THERAPY CONNOR, JAMES R. 2015-03-05 US disclosed
WO-2013024447-A1 COMPOUNDS FOR USE IN CANCER THERAPY NUHOPE, LLC (US) 2013-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134691-A1 BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY MGMT, BCL2, BAX MAPT 2828/4885MEN1 2410/4885KMT2A 2749/4885
US-20150065531-A1 COMPOUNDS FOR USE IN CANCER THERAPY MGMT, BCL2, BAK1 MAPT 3272/4885MEN1 1885/4885KMT2A 3262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.